Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 04:00PM ET
3.28
Dollar change
-0.06
Percentage change
-1.84
%
Index- P/E- EPS (ttm)-0.69 Insider Own- Shs Outstand18.22M Perf Week1.27%
Market Cap59.73M Forward P/E- EPS next Y-1.08 Insider Trans- Shs Float- Perf Month-0.65%
Income-12.59M PEG- EPS next Q- Inst Own5.35% Short Float- Perf Quarter-20.23%
Sales0.00M P/S- EPS this Y-67.07% Inst Trans- Short Ratio0.71 Perf Half Y-36.95%
Book/sh1.24 P/B2.65 EPS next Y-17.86% ROA- Short Interest0.00M Perf Year-47.04%
Cash/sh1.14 P/C2.88 EPS next 5Y- ROE- 52W Range2.20 - 6.39 Perf YTD-33.77%
Dividend Est.- P/FCF- EPS past 5Y-24.90% ROI-55.78% 52W High-48.69% Beta0.78
Dividend TTM- Quick Ratio12.25 Sales past 5Y0.00% Gross Margin- 52W Low49.02% ATR (14)0.19
Dividend Ex-Date- Current Ratio12.25 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)50.27 Volatility2.15% 2.89%
Employees14 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price25.22
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q- Payout- Rel Volume0.01 Prev Close3.34
Sales Surprise- EPS Surprise28.25% Sales Q/Q- EarningsFeb 28 Avg Volume4.75K Price3.28
SMA201.09% SMA50-0.56% SMA200-26.28% Trades Volume34 Change-1.84%
Date Action Analyst Rating Change Price Target Change
Jun-29-23Resumed ROTH MKM Buy $15
Jul-25-22Initiated H.C. Wainwright Buy $25
Jan-13-22Initiated Maxim Group Buy $21
May-28-24 06:10AM
May-06-24 06:25AM
Feb-08-24 05:00AM
Sep-06-23 07:00AM
Jul-28-23 03:00AM
09:57AM Loading…
Jul-08-23 09:57AM
Jun-29-23 07:00AM
May-17-23 06:34AM
May-16-23 07:00AM
May-09-23 07:15AM
May-02-23 03:30PM
Apr-26-23 07:00AM
Apr-03-23 07:00AM
Mar-02-23 06:45AM
Feb-07-23 07:00AM
07:45AM Loading…
Jan-29-23 07:45AM
Dec-08-22 05:16AM
Nov-07-22 08:05AM
Oct-24-22 07:30AM
Oct-17-22 10:27AM
Oct-05-22 08:05AM
Sep-07-22 07:00AM
Aug-22-22 07:06AM
Jul-25-22 06:00AM
May-27-22 09:40AM
May-13-22 07:30AM
May-09-22 07:30AM
May-04-22 04:30PM
07:30AM
May-02-22 04:30PM
07:30AM Loading…
Apr-27-22 07:30AM
Apr-20-22 07:30AM
Mar-15-22 06:34AM
Mar-09-22 07:46AM
Feb-24-22 07:30AM
Dec-17-21 04:15PM
Dec-14-21 10:36PM
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.